Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07935941
PHASE1

A Phase I Study of HLX109 in Healthy Participants

Sponsor: Shanghai Henlius Biotech

View on ClinicalTrials.gov

Summary

This study is a randomized, double-Blind, single ascending dose, phase I clinical study to evaluate safety, tolerability and pharmacokinetic profiles of HLX109 in healthy participants

Official title: A Randomized, Double-Blind, Single Ascending Dose, Phase I Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetic Profiles of HLX109 in Healthy Participants

Key Details

Gender

All

Age Range

18 Years - 55 Years

Study Type

INTERVENTIONAL

Enrollment

64

Start Date

2026-11-18

Completion Date

2027-11-20

Last Updated

2026-11-18

Healthy Volunteers

Yes

Interventions

DRUG

HLX109

HLX109: A mg, SC, single dose

DRUG

HLX109

HLX109: B mg, SC, single dose

DRUG

HLX109

HLX109: C mg, SC, single dose

DRUG

HLX109

HLX109: D mg, SC, single dose

DRUG

HLX109

HLX109: E mg, SC, single dose

DRUG

HLX109

HLX109: F mg, SC, single dose

DRUG

HLX109

HLX109: G mg, SC, single dose

DRUG

Placebo

Placebo: A mg, SC, single dose

DRUG

Placebo

Placebo: B mg, SC, single dose

DRUG

Placebo

Placebo: C mg, SC, single dose

DRUG

Placebo

Placebo: D mg, SC, single dose

DRUG

Placebo

Placebo: E mg, SC, single dose

DRUG

Placebo

Placebo: F mg, SC, single dose

DRUG

Placebo

Placebo: G mg, SC, single dose

Locations (2)

Nucleus Network Melbourne

Melbourne, Australia

The Second Affiliated Hospital of Anhui Medical University

Hefei, Anhui, China